Homepage Top Section2

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune

The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,

The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is

The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,

The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in